How should dulaglutide (Trulicity) be managed in an 87-year-old male patient with diabetes during his follow‑up visit?

Management of Dulaglutide (Trulicity) in an 87-Year-Old Male with Diabetes

Continue dulaglutide if the patient is functionally stable with good quality of life, but critically reassess treatment goals focusing on hypoglycemia prevention rather than strict glycemic targets, and consider simplification or discontinuation if the patient has declining functional status, limited life expectancy, or significant gastrointestinal side effects.

Key Management Principles for This Age Group

The 2025 ADA guidelines for older adults emphasize that diabetes management in patients aged 87 should prioritize prevention of hypoglycemia, hyperglycemia-related symptoms, and preservation of quality of life over achieving strict HbA1c targets 1. The approach depends entirely on the patient's functional status and life expectancy.

Clinical Assessment Framework

Categorize your patient into one of three groups 1:

1. Stable Individual (functionally independent, good quality of life)

• Continue dulaglutide with current medication plan
• Primary focus: preventing hypoglycemia while managing symptomatic hyperglycemia
• Monitor for gastrointestinal side effects (nausea, reduced appetite, weight loss)
• Critical consideration: GLP-1 agonists like dulaglutide can cause significant weight loss and gastrointestinal symptoms 2, which may be problematic in frail elderly patients

2. Individual with Organ Failure or Declining Function

• Preventing hypoglycemia becomes paramount 1
• Consider dose reduction or discontinuation of dulaglutide if:
  • Patient has poor oral intake
  • Experiencing unintended weight loss
  • Gastrointestinal symptoms affecting nutrition
• Dulaglutide has low inherent hypoglycemia risk when used alone 3, making it safer than sulfonylureas or insulin in this context
• Allow glucose values in the upper range of goals

3. Palliative Care or End-of-Life

• Discontinue dulaglutide 1
• Agents causing gastrointestinal symptoms or excess weight loss are not appropriate in this setting
• Focus shifts entirely to comfort and symptom management

Specific Advantages and Concerns for Dulaglutide in This Population

Advantages:

• Once-weekly dosing improves adherence 4
• Low hypoglycemia risk when not combined with insulin or sulfonylureas 3
• Cardiovascular benefits demonstrated in REWIND trial (12% reduction in MACE) 5
• No dose adjustment needed for age, weight, or renal function (though caution in severe renal disease) 2

Concerns in 87-year-olds:

• Gastrointestinal side effects (nausea, vomiting, diarrhea) occur in 47% of patients 5, which can lead to dehydration and poor nutrition in elderly
• Weight loss averaging 1-3 kg 2 may be detrimental if patient is already frail or sarcopenic
• Risk of acute pancreatitis, though rare 6

Practical Management Algorithm

Step 1: Assess functional status and life expectancy

• If limited (<5 years) or declining function → consider discontinuation
• If stable and functional → continue with monitoring

Step 2: Evaluate current tolerability

• Check for gastrointestinal symptoms, unintended weight loss, or reduced oral intake
• If present and affecting quality of life → discontinue or switch to simpler regimen

Step 3: Adjust glycemic targets

• Relax HbA1c goals to 7.5-8.5% or higher based on functional status 1
• Avoid targeting HbA1c <7% in this age group unless patient is exceptionally healthy

Step 4: Monitor appropriately

• Reduce frequency of glucose monitoring if burdensome 1
• Consider CGM if frequent fingersticks affect quality of life but monitoring still needed

Common Pitfalls to Avoid

1. Over-treating to strict targets: An HbA1c of 7.0% is NOT appropriate for most 87-year-olds
2. Ignoring gastrointestinal symptoms: These can lead to malnutrition and dehydration in elderly
3. Continuing all medications reflexively: Deintensification is often appropriate and improves quality of life 1
4. Not involving patient/family in goals of care discussion: Essential at this age 1

When to Discontinue

Discontinue dulaglutide if:

• Patient enters palliative care or hospice
• Significant gastrointestinal side effects affecting nutrition
• Unintended weight loss >5% body weight
• Poor oral intake or declining functional status
• Patient/family preference after goals of care discussion

Alternative Approaches

If discontinuing dulaglutide, consider:

• Metformin alone (if tolerated and no contraindications)
• SGLT2 inhibitors (cardiovascular benefits, but dehydration risk in elderly)
• Basal insulin at conservative doses if needed for symptomatic hyperglycemia
• No medication if patient is stable and asymptomatic

The endocrinology consultation may be warranted if the patient has recurrent hypoglycemia, multiple complications, or complex medication regimens requiring adjustment 7.